A phase II study of radioimmunotherapy with intraventricular 131I-3F8 for medulloblastoma Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Neoplasm
  • Immunoglobulin Fragments
  • Neoplasms, Experimental

abstract

  • cRIT with (131) I-3F8 is safe, has favorable dosimetry to CSF, and when added to salvage therapy using conventional modalities, may have clinical utility in maintaining remission in high-risk or recurrent MB.

publication date

  • January 2017

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1002/pbc.26754

PubMed ID

  • 28940863

Additional Document Info